Cargando…

A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1

BACKGROUND: Aberrant activation of the Wnt/β-catenin pathway is a major and frequent event in liver cancer, but inhibition of oncogenic β-catenin signaling has proven challenging. The identification of genes that are synthetically lethal in β-catenin-activated cancer cells would provide new targets...

Descripción completa

Detalles Bibliográficos
Autores principales: Canal, Frédéric, Anthony, Elodie, Lescure, Aurianne, Del Nery, Elaine, Camonis, Jacques, Perez, Franck, Ragazzon, Bruno, Perret, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696130/
https://www.ncbi.nlm.nih.gov/pubmed/26715116
http://dx.doi.org/10.1186/s12885-015-2037-8
_version_ 1782407733075509248
author Canal, Frédéric
Anthony, Elodie
Lescure, Aurianne
Del Nery, Elaine
Camonis, Jacques
Perez, Franck
Ragazzon, Bruno
Perret, Christine
author_facet Canal, Frédéric
Anthony, Elodie
Lescure, Aurianne
Del Nery, Elaine
Camonis, Jacques
Perez, Franck
Ragazzon, Bruno
Perret, Christine
author_sort Canal, Frédéric
collection PubMed
description BACKGROUND: Aberrant activation of the Wnt/β-catenin pathway is a major and frequent event in liver cancer, but inhibition of oncogenic β-catenin signaling has proven challenging. The identification of genes that are synthetically lethal in β-catenin-activated cancer cells would provide new targets for therapeutic drug design. METHODS: We transfected the parental HuH6 hepatoblastoma cell line with a doxycycline-inducible shRNA against CTNNB1 (gene coding for β-catenin) to obtain an isogenic cell line pair with or without aberrant β-catenin signaling. Using this hepatoblastoma isogenic cell line pair, we performed a human kinome-wide siRNA screen to identify synthetic lethal interactions with oncogenic CTNNB1. The phenotypic readouts of the screen were cell proliferation, cell cycle arrest and apoptosis, which were assessed by image-based analysis. In addition, apoptosis was assessed by flow cytometric experiments and immunoblotting. The potential synthetic lethal relationship between candidates genes identified in the screen and oncogenic CTNNB1 was also investigated in a different cellular context, a colorectal HCT116 isogenic cell line pair. RESULTS: We first determined the experimental conditions that led to the efficient expression of shRNA against CTNNB1 and maximal reduction of β-catenin signaling activity in response to doxycycline treatment. Following high throughput screening in which 687 genes coding for kinases and proteins related to kinases (such as pseudokinases and phosphatases) were targeted, we identified 52 genes required for HuH6 survival. The silencing of five of these genes selectively impaired the viability of HuH6 cells with high β-catenin signaling: HGS, STRADA, FES, BRAF and PKMYT1. Among these candidates, HGS depletion had the strongest inhibitory effect on cell growth and led to apoptosis specifically in HuH6 with high β-catenin activity, while HuH6 with low β-catenin activity were spared. In addition, HGS was identified as a potential synthetic lethal partner of oncogenic CTNNB1 in the HCT116 colorectal isogenic cell line pair. CONCLUSIONS: These results demonstrate the existence of crosstalk between β-catenin signaling and HGS. Importantly, HGS depletion specifically affected cells with uncontrolled β-catenin signaling activity in two different types of cancer (Hepatoblastoma HuH6 and colorectal HCT116), and thus may represent a new potential target for novel therapeutic strategies in liver and colorectal cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-2037-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4696130
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46961302015-12-31 A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1 Canal, Frédéric Anthony, Elodie Lescure, Aurianne Del Nery, Elaine Camonis, Jacques Perez, Franck Ragazzon, Bruno Perret, Christine BMC Cancer Research Article BACKGROUND: Aberrant activation of the Wnt/β-catenin pathway is a major and frequent event in liver cancer, but inhibition of oncogenic β-catenin signaling has proven challenging. The identification of genes that are synthetically lethal in β-catenin-activated cancer cells would provide new targets for therapeutic drug design. METHODS: We transfected the parental HuH6 hepatoblastoma cell line with a doxycycline-inducible shRNA against CTNNB1 (gene coding for β-catenin) to obtain an isogenic cell line pair with or without aberrant β-catenin signaling. Using this hepatoblastoma isogenic cell line pair, we performed a human kinome-wide siRNA screen to identify synthetic lethal interactions with oncogenic CTNNB1. The phenotypic readouts of the screen were cell proliferation, cell cycle arrest and apoptosis, which were assessed by image-based analysis. In addition, apoptosis was assessed by flow cytometric experiments and immunoblotting. The potential synthetic lethal relationship between candidates genes identified in the screen and oncogenic CTNNB1 was also investigated in a different cellular context, a colorectal HCT116 isogenic cell line pair. RESULTS: We first determined the experimental conditions that led to the efficient expression of shRNA against CTNNB1 and maximal reduction of β-catenin signaling activity in response to doxycycline treatment. Following high throughput screening in which 687 genes coding for kinases and proteins related to kinases (such as pseudokinases and phosphatases) were targeted, we identified 52 genes required for HuH6 survival. The silencing of five of these genes selectively impaired the viability of HuH6 cells with high β-catenin signaling: HGS, STRADA, FES, BRAF and PKMYT1. Among these candidates, HGS depletion had the strongest inhibitory effect on cell growth and led to apoptosis specifically in HuH6 with high β-catenin activity, while HuH6 with low β-catenin activity were spared. In addition, HGS was identified as a potential synthetic lethal partner of oncogenic CTNNB1 in the HCT116 colorectal isogenic cell line pair. CONCLUSIONS: These results demonstrate the existence of crosstalk between β-catenin signaling and HGS. Importantly, HGS depletion specifically affected cells with uncontrolled β-catenin signaling activity in two different types of cancer (Hepatoblastoma HuH6 and colorectal HCT116), and thus may represent a new potential target for novel therapeutic strategies in liver and colorectal cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-2037-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-29 /pmc/articles/PMC4696130/ /pubmed/26715116 http://dx.doi.org/10.1186/s12885-015-2037-8 Text en © Canal et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Canal, Frédéric
Anthony, Elodie
Lescure, Aurianne
Del Nery, Elaine
Camonis, Jacques
Perez, Franck
Ragazzon, Bruno
Perret, Christine
A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title_full A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title_fullStr A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title_full_unstemmed A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title_short A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1
title_sort kinome sirna screen identifies hgs as a potential target for liver cancers with oncogenic mutations in ctnnb1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696130/
https://www.ncbi.nlm.nih.gov/pubmed/26715116
http://dx.doi.org/10.1186/s12885-015-2037-8
work_keys_str_mv AT canalfrederic akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT anthonyelodie akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT lescureaurianne akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT delneryelaine akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT camonisjacques akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT perezfranck akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT ragazzonbruno akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT perretchristine akinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT canalfrederic kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT anthonyelodie kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT lescureaurianne kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT delneryelaine kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT camonisjacques kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT perezfranck kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT ragazzonbruno kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1
AT perretchristine kinomesirnascreenidentifieshgsasapotentialtargetforlivercancerswithoncogenicmutationsinctnnb1